MIAMI -- Jean-Marc D. Quach, a longtime leader in healthcare management and marketing, has been named executive director of The Alpha-1 Project, a subsidiary of the Alpha-1 Foundation.
Quach, of Englewood Cliffs, NJ, is not a newcomer to the world of Alpha-1 Antitrypsin Deficiency. From 1999-2004, he was vice president and general manager of Express Scripts Specialty Distribution Services, where he worked with AlphaNet and Bayer to create a "direct distribution" model for Prolastin®, then the only Alpha-1 augmentation treatment available. The business model is still used for orphan and other high-risk or shortage-prone drug products.
“Jean-Marc, with his record of leadership and innovation, is the perfect match for the Foundation’s initiative to speed the development of new therapies for Alpha-1,” said John W. Walsh, Foundation president and CEO.
The Alpha-1 Project (TAP) is a for-profit, wholly owned subsidiary of the not-for-profit Alpha-1 Foundation. “TAP is a venture philanthropy company,” said Marcia F. Ritchie, vice president and chief operating officer of both TAP and the Alpha-1 Foundation. “The goal is to accelerate the discovery, development and commercialization of treatments and drug therapies for those with Alpha-1,” Ritchie said.